GammaTile® brachytherapy in the treatment of recurrent glioblastomas

BACKGROUND: GammaTile® (GT) is a recent U.S. Food and Drug Administration (FDA) cleared brachytherapy platform. Here, we report clinical outcomes for recurrent glioblastoma patients after GT treatment following maximal safe resection. METHODS: We prospectively followed twenty-two consecutive Isocitr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gessler, Dominic J, Neil, Elizabeth C, Shah, Rena, Levine, Joseph, Shanks, James, Wilke, Christopher, Reynolds, Margaret, Zhang, Shunqing, Özütemiz, Can, Gencturk, Mehmet, Folkertsma, Mark, Bell, W Robert, Chen, Liam, Ferreira, Clara, Dusenbery, Kathryn, Chen, Clark C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788013/
https://www.ncbi.nlm.nih.gov/pubmed/35088050
http://dx.doi.org/10.1093/noajnl/vdab185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788013/
https://www.ncbi.nlm.nih.gov/pubmed/35088050
http://dx.doi.org/10.1093/noajnl/vdab185

Ejemplares similares